June 29, 2022

New results on Proclarix® resolving indeterminate Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 37th Annual EAU Congress in Amsterdam, NL.

Zurich-Schlieren, Switzerland, June 29, 2022  - Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new data will be presented showing that Proclarix® can be used with high confidence by reliably identifying clinically significant prostate cancer and safely ruling out negative cases.

Study results will be presented during the 37th Annual European Association of Urology (EAU) Congress in Amsterdam, NL in the following session:

Abstract Session 26: PCa localised imaging grade prediction, reporting and markers – Sunday, July 03 2022, 10:30 - 12:00, Yellow Area, Room Forum.

Abstract A0481 – A0481: Proclarix aids in resolving indeterminate multi-parametric magnetic resonance imaging for the improved diagnosis of prostate cancer.

Presenter: M. Campistol Torres, Universitat Autònoma de Barcelona, Vall d’Hebron University Hospital, Barcelona, Spain.

Authors: Campistol Torres M. (1), Morote J.(1), Pye H.(2), Athanasiou A.(3), Celma A.(1), Regis L.(1), Planas J.(1), Santamaria A.(1), Trilla E.(1), Schiess R.(3), Punwani S.(4), Whitaker H.(2), Ahmed H.U.(5), Emberton M.(6)

Institutions: (1)Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Dept. of Urology, Barcelona, Spain, (2)University College London, Molecular Diagnostics and Therapeutics Group, London, United Kingdom, (3)Proteomedix AG, Dept. of Research & Development, Zurich-Schlieren, Switzerland, (4)University College London, Centre for Medical Imaging, London, United Kingdom, (5)Imperial College London, Dept. of Surgery and Cancer, London, United Kingdom, (6)University College London, Division of Surgery and Interventional Science, London, United Kingdom

About Proclarix®

Proclarix® is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.

About Proteomedix

Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.

For further details, please contact:

Dr. Ralph Schiess, CSO

schiess@proteomedix.com, +41 44 733 40 90


Download Press Release in English